Investors Buy High Volume of Put Options on Gilead Sciences (GILD)
Gilead Sciences (NASDAQ:GILD) saw unusually large options trading activity on Monday. Investors acquired 10,838 put options on the company, AnalystRatings.NET reports. This is an increase of 110% compared to the average volume of 5,168 put options.
GILD has been the subject of a number of recent research reports. Analysts at UBS AG reiterated a “buy” rating on shares of Gilead Sciences in a research note to investors on Monday. They now have a $102.00 price target on the stock, up previously from $80.00. Separately, analysts at Citigroup Inc. raised their price target on shares of Gilead Sciences to $96.00 in a research note to investors on Monday. Finally, analysts at Maxim Group raised their price target on shares of Gilead Sciences from $89.00 to $98.00 in a research note to investors on Thursday, January 2nd. They now have a “buy” rating on the stock. Two analysts have rated the stock with a hold rating and twenty-four have issued a buy rating to the stock. Gilead Sciences presently has a consensus rating of “Buy” and a consensus price target of $80.04.
Shares of Gilead Sciences (NASDAQ:GILD) opened at 73.74 on Tuesday. Gilead Sciences has a 52-week low of $38.27 and a 52-week high of $76.11. The stock has a 50-day moving average of $73.23 and a 200-day moving average of $64.27. The company has a market cap of $113.1 billion and a P/E ratio of 40.31.
Gilead Sciences (NASDAQ:GILD) last released its earnings data on Tuesday, October 29th. The company reported $0.52 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.48 by $0.04. The company had revenue of $2.78 billion for the quarter, compared to the consensus estimate of $2.72 billion. During the same quarter in the previous year, the company posted $1.00 earnings per share. The company’s revenue for the quarter was up 14.7% on a year-over-year basis. Analysts expect that Gilead Sciences will post $2.00 EPS for the current fiscal year.
Gilead Sciences, Inc (NASDAQ:GILD) is a research-based biopharmaceutical company that discovers, develops and commercializes medicines.
Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.